JP2021535140A5 - - Google Patents
Info
- Publication number
- JP2021535140A5 JP2021535140A5 JP2021510639A JP2021510639A JP2021535140A5 JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5 JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- naturally
- antibody fragment
- molecule
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050991A JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862723793P | 2018-08-28 | 2018-08-28 | |
| US62/723,793 | 2018-08-28 | ||
| PCT/US2019/048677 WO2020047176A1 (en) | 2018-08-28 | 2019-08-28 | Anti-cd3 antibody folate bioconjugates and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050991A Division JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535140A JP2021535140A (ja) | 2021-12-16 |
| JP2021535140A5 true JP2021535140A5 (https=) | 2022-09-06 |
| JP7759805B2 JP7759805B2 (ja) | 2025-10-24 |
Family
ID=68051890
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510639A Active JP7759805B2 (ja) | 2018-08-28 | 2019-08-28 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
| JP2025050991A Pending JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050991A Pending JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12377294B2 (https=) |
| EP (1) | EP3844188A1 (https=) |
| JP (2) | JP7759805B2 (https=) |
| KR (1) | KR20210063351A (https=) |
| CN (1) | CN111417655A (https=) |
| AU (1) | AU2019327456A1 (https=) |
| BR (1) | BR112021003843A2 (https=) |
| CA (1) | CA3110647A1 (https=) |
| IL (1) | IL281076A (https=) |
| MX (1) | MX2021002301A (https=) |
| SG (1) | SG11202101875VA (https=) |
| WO (1) | WO2020047176A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018005232A (es) * | 2015-11-03 | 2018-08-15 | Ambrx Inc | Anticuerpos anti-cd3 novedosos y sus usos. |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2021173889A1 (en) * | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP7518286B2 (ja) | 2020-08-25 | 2024-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| EP0092227B1 (en) | 1982-04-19 | 1988-07-27 | Nissan Motor Co., Ltd. | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
| AU773915B2 (en) | 1999-04-28 | 2004-06-10 | Georgetown University | Ligands for metabotropic glutamate receptors |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| JP4638225B2 (ja) | 2002-05-30 | 2011-02-23 | ザ スクリプス リサーチ インスティテュート | 銅を触媒とするアジドとアセチレンのライゲーション |
| ZA200503075B (en) * | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| EP2399893B1 (en) | 2004-12-22 | 2018-08-15 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
| JP5773382B2 (ja) | 2010-12-29 | 2015-09-02 | 株式会社Sumco | シリカガラスルツボ及びその製造方法 |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| KR102190832B1 (ko) | 2012-06-19 | 2020-12-15 | 암브룩스, 인코포레이티드 | 항cd70 항체 약물 컨쥬게이트 |
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| IL256562B2 (en) * | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
| MX2018005232A (es) | 2015-11-03 | 2018-08-15 | Ambrx Inc | Anticuerpos anti-cd3 novedosos y sus usos. |
| KR102891788B1 (ko) * | 2016-02-04 | 2025-11-26 | 더 스크립스 리서치 인스티튜트 | 인간화 항-cd3 항체, 접합체 및 이의 용도 |
-
2019
- 2019-08-28 MX MX2021002301A patent/MX2021002301A/es unknown
- 2019-08-28 CN CN201980004962.5A patent/CN111417655A/zh active Pending
- 2019-08-28 SG SG11202101875VA patent/SG11202101875VA/en unknown
- 2019-08-28 WO PCT/US2019/048677 patent/WO2020047176A1/en not_active Ceased
- 2019-08-28 AU AU2019327456A patent/AU2019327456A1/en not_active Abandoned
- 2019-08-28 US US17/272,241 patent/US12377294B2/en active Active
- 2019-08-28 KR KR1020217009160A patent/KR20210063351A/ko not_active Ceased
- 2019-08-28 EP EP19773581.4A patent/EP3844188A1/en active Pending
- 2019-08-28 CA CA3110647A patent/CA3110647A1/en active Pending
- 2019-08-28 BR BR112021003843-4A patent/BR112021003843A2/pt unknown
- 2019-08-28 JP JP2021510639A patent/JP7759805B2/ja active Active
-
2021
- 2021-02-24 IL IL281076A patent/IL281076A/en unknown
-
2025
- 2025-03-26 JP JP2025050991A patent/JP2025098156A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535140A5 (https=) | ||
| JP2024123231A5 (https=) | ||
| TWI250988B (en) | Thrombopoietic compounds | |
| US6177404B1 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| IL323631A (en) | Compositions containing, methods and uses of antibody-TLR agonist conjugates | |
| IL273285B1 (en) | Anti- folate receptor alpha antibody conjugates and their uses | |
| US6391305B1 (en) | Conjugates useful in the treatment of prostate cancer | |
| JP2022520792A5 (https=) | ||
| IL317851A (en) | IL-15 conjugates and their use | |
| CN108066772B (zh) | 靶向tacstd2的抗体与药物偶联体(adc)分子 | |
| CN110698565A (zh) | 靶向肿瘤的CD38-pHLIP融合肽 | |
| JP2012116864A (ja) | Ｇｌｐ−１化合物 | |
| JP2002543111A (ja) | ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅 | |
| CN115175917A (zh) | 药物缀合物及其应用 | |
| SK57399A3 (en) | Conjugates useful in the treatment of prostate cancer | |
| CN107206103A (zh) | 用于治疗目的的抗体‑脲酶缀合物 | |
| JP2022512746A5 (https=) | ||
| CN115916801A (zh) | 新型的α螺旋双性细胞穿透肽及其用途 | |
| US20030232760A1 (en) | Conjugates useful in the treatment of prostate cancer | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| JP6656661B2 (ja) | プレキシンの結合調節剤 | |
| CN115697375A (zh) | 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物 | |
| HK1243105A1 (en) | High activity tumour inhibitor and preparation method and use thereof | |
| WO2014044793A2 (en) | Cd22-binding peptides | |
| EP3059243A1 (en) | Yap protein inhibiting polypeptide and application thereof |